Slide 1: Teleflex Incorporated Second Quarter 2026 Earnings Conference Call
Teleflex Incorporated Second Quarter 2026 Earnings Conference Call 8/6/2026
Slide 2: Conference Call Logistics
Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on August 6, 2026 either on the Teleflex website or by telephone. The call can
Slide 3: Today's Speakers
Today’s Speakers Jason John Deren Lawrence Weidman Executive VP Keusch President and CEO and CFO VP, Investor Relations and Strategy Development TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026
Slide 4: Note on Forward-Looking Statements and Non-GAAP Financial Measures
Note on Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, our forecasted 2026: GAAP, pro forma adjusted revenue and pro forma adjusted constant currency revenue growth, GAAP and adjusted operating margin and GAAP and adjusted earnings pe
Slide 5: Executive Overview
Executive Overview Jason Weidman President and CEO
Slide 6: Q2 Performance Summary
Q2'26 Highlights Q2 ◦ Q2'26 pro forma adjusted constant currency revenue grew 4.7% year-over-year Performance ◦ Q2'26 adjusted gross margin of 61.7% and adjusted operating margin of 19.6% Summary ◦ Q2'26 adjusted EPS of $1.76, a 1.7% increase year-over-year ◦ Closed the OEM Strategic Divestiture for
Slide 7: Innovation Updates
Innovation Updates EZPLAZTM Freeze Dried Plasma Receives FDA BLA Approval FDA BLA APPROVAL – First freeze dried plasma licensed by the FDA; expands the emergency medicine portfolio within our EZPLAZTM Vascular and Emergency Medicine business Freeze Dried Plasma – Approved for transfusion in adults w
Slide 8: Innovation Updates
Innovation Updates BIOMAG-I: Four-Year Data Confirms Durable FreesolveTM Resorbable Magnesium Scaffold (RMS) Performance – Announced four-year follow-up data from the single-arm BIOMAG-I study, confirming the long-term, Differentiated sustained performance of FreesolveTM RMS 1 Freesolve combines tem
Slide 9: Q2'26 Global Product Commentary of Continuing Operations
Q2'26 Global Product Commentary of Continuing Operations Sales ($M) Commentary $246.3 Vascular Reported rev. growth: 9.0% • In Q2'26 growth was primarily driven by growth in hemostatic products and the central access portfolio Pro forma adj. const. curr. rev. growth: 8.0% $211.9 Interventional Repor
Slide 10: Q2'26 Global Product Category Revenue Review
Q2'26 Global Product Category Revenue Review Three Months Ended June 30, 2026 June 30, 2026 June 29, 2025 % Increase / (Decrease) Pro Forma Pro Forma Pro Forma Adjusted Reported Reported Reported Adjustment Adjustment Adjusted Adjustment Adjusted Revenue Growth Currency Impact Constant Revenue Reven
Slide 11: Financial Overview
Financial Overview John Deren Executive VP and CFO
Slide 12: Q2'26 Financial Review of Continuing Operations
Q2'26 Financial Review of Continuing Operations Adjusted GAAP 2025 64.5% 2025 60.1% ◦ The year-over-year adjusted gross margin decline was primarily driven by the following: Gross Margin (280) bps ◦ the adverse impact of tariffs ◦ the addition of the Vascular Intervention business, which has a sligh
Slide 13: Capital Allocation Strategy Update
Capital Allocation Strategy Update Capital return commitment • $1 billion share repurchase authorization and $800 million reduction in debt • Near-term capital return to shareholders to be primarily funded by after-tax proceeds from the Strategic Divestitures Q2 share repurchases • Repurchased appro
Slide 14: 2026 Financial Guidance
2026 Financial Guidance ◦ Reducing 2026 pro forma adjusted constant currency revenue growth range to 3.50% to 4.5% year-over-year Revenue ◦ Reducing 2026 GAAP revenue from continuing operations growth range to 13.40% to 14.4% year-over-year Earnings Per ◦ Increasing 2026 Adjusted diluted EPS from co
Slide 15: 2026 Guidance Considerations
2026 Guidance Considerations ◦ 3.50% to 4.5% pro forma adjusted constant currency revenue growth for 2026 Pro Forma Adj. CC ◦ Excludes foreign exchange, Italian payback matter, and discontinued products Revenue Growth ◦ Includes Vascular Intervention revenue for the first half of 2025 ◦ 2026 adjuste
Slide 16: 2026 Financial Guidance – Future Opportunities
2026 Financial Guidance – Future Opportunities ◦ TS/MS agreements expected to offset stranded costs on an annualized basis Adjusted Operating ◦ Previously announced restructuring programs to result in ~$50 million of pre-tax Margin savings on an annualized basis upon completion in mid-2028, which wi
Slide 17: 2026 Financial Guidance of Continuing Operations Summary
2026 Financial Guidance of Continuing Operations Summary 2026 Guidance Low High GAAP Revenue Growth 13.4% 14.4% Impact of Vascular Intervention Pro Forma 10.0% 10.0% Impact of Discontinued Product (0.7)% (0.7)% Impact of Italian Payback Measure (0.5)% (0.5)% Base Year Adjustment (GAAP Versus Pro For
Slide 18: Forecasted 2026 Pro Forma Adjusted Revenue Reconciliation
Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation 2026 Guidance 2026 Guidance 2025 Low High GAAP revenue $1,992.7 $2,260 $2,280 Vascular Intervention pro forma adjustment 199.0 — — Discontinued product adjustment (14.3) — — Italian payback measure adjustment (9.0)
Slide 19: Key Takeaways
Key Takeaways Solid Q2 Performance Committed to Significant Portfolio Transformation but with Interventional Capital Return to Positions for Integration Challenges Shareholders Acceleration in 2027+ • Vascular & Surgical delivered • Executing to total of $1B share • Successfully executing towards ex
Slide 20: Thank You!
Thank You! 20 TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026
Slide 21: Appendices
Appendices Empowering the future of healthcare
Slide 22: Non-GAAP Financial Measures
Non-GAAP Financial Measures The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: Pro forma adjusted revenue. This non-GA
Slide 23: Non-GAAP Financial Measures
Non-GAAP Financial Measures Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring and optimizat
Slide 24: Non-GAAP Adjustments
Non-GAAP Adjustments The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring and optimization charges - Restructuring and optimi
Slide 25: Non-GAAP Adjustments
Non-GAAP Adjustments Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings esta
Slide 26: Appendix A1 – 2026 Global Product Category Revenue Review
Appendix A1 – 2026 Global Product Category Revenue Review Six Months Ended June 30, 2026 June 30, 2026 June 29, 2025 % Increase / (Decrease) Pro Forma Pro Forma Pro Forma Adjusted Reported Reported Reported Adjustment Adjustment Adjusted Adjustment Adjusted Revenue Growth Currency Impact Constant Re
Slide 27: Appendix B1 – Reconciliation of Consolidated Statement of Income Items
Appendix B1 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended June 30, 2026 Operating Income Income tax Effective Diluted earnings per share Revenue Gross margin SG&A (1) R&D (1) margin (2) before expense income tax from contin
Slide 28: Appendix B2 – Reconciliation of Consolidated Statement of Income Items
Appendix B2 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Three Months Ended June 29, 2025 Income Effective Diluted earnings Revenue Gross SG&A (1) R&D (1) Operating before Income tax income tax per share from margin margin (2) income taxes e
Slide 29: Appendix B3 – Reconciliation of Consolidated Statement of Income Items
Appendix B3 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Six Months Ended June 30, 2026 Operating Income Income tax Effective Diluted earnings per share Revenue Gross margin SG&A (1) R&D (1) margin (2) before expense income tax from continui
Slide 30: Appendix B4 – Reconciliation of Consolidated Statement of Income Items
Appendix B4 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) Six Months Ended June 29, 2025 Diluted earnings Revenue Gross SG&A (1) R&D (1) Operating Income before Income tax Effective per share from margin margin (2) income taxes expense income
Slide 31: Appendix B Tickmarks
A. Restructuring and optimization charges – For the three months ended June 30, 2026, pre-tax restructuring charges were $0.2 million and restructuring related charges were $10.6 million. For the three months ended June 29, 2025, pre-tax restructuring charges were $1.3 million, restructuring related
Slide 32: Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation
Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation Forecasted GAAP Operating Margin 9.4% Estimated restructuring and optimization items 2.2% Estimated acquisition, integration and divestiture related items 1.8% Estimated other items (1.2)% Estimated ERP implementation 0.7% Estimated int
Slide 33: Appendix D - Reconciliation of Forecasted 2026 Adjusted EPS Guidance
Appendix D - Reconciliation of Forecasted 2026 Adjusted Earnings Per Share Guidance Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $2.54 $2.84 Restructuring and optimization items, net of tax $0.98 $0.98 Acquisition, integration and divestiture related items, net of t
Slide 34: 2026 Financial Review - Six Months Ended June 30, 2026
2026 Financial Review - Six Months Ended June 30, 2026 ◦ Pro Forma adjusted revenue increased 4.9% year-over-year on a constant currency basis Global revenue growth ◦ Revenue increased 30.6% year-over-year on a GAAP basis ◦ Adjusted gross margin of 61.5%, down 370 bps year-over-year Gross margin ◦ G
Slide 35: Indications and Important Safety Information for EZPLAZ Freeze Dried Plasma
Rx Only INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR EZPLAZ™ FREEZE DRIED PLASMA INDICATIONS EZPLAZ™ Freeze Dried Plasma (FDP) is indicated for transfusion in adults when plasma is required and other plasma products are not available. Indications include: • Management of preoperative or bleeding